MD Biosciences Blog

What is the Impact of Vendor Animal Microbiomes on Disease?

Posted by MD Biosciences on Apr 22, 2016 2:35:00 PM

On Thusday, MD Biosciences' Lead Scientist Britnie James, Ph.D. presented at the 2nd Annual Translational Microbiome Conference held in Boston, MA.  Her talk entitled "Understanding the Impact of Animal Vendors and the Microbiome in Tumor Progression and Treatment in a Model of Metastatic Breast Cancer" highlights the importance of the role of the micorbiome in disease progression and treatment. 

Read More

Topics: Inflammation, cancer/tumor, Microbiome

2015 Recap|Clinical Diagnostics & Translational Research

Posted by MD Biosciences on Dec 17, 2015 4:57:36 PM

As we wind down to years end, we at MD Biosciences would like to thank everyone, especially our collaborators, for making this year a success. We have undergone significant growth that we expect to continue throughout the upcoming year.

Read More

Topics: Pain, Inflammation, Neuro/CNS, post-operative pain, cancer/tumor, Microbiome, Biomarkers, CLIA, Neuropathy

Targeting Microbiomes & Biomarkers: Inflammation World Congress

Posted by MD Biosciences on Aug 20, 2015 3:30:00 PM


The 12th World Congress on Inflammation wrapped up on Wednesday August 12th after four days packed with cutting edge inflammatory research by key opinions leaders in the field. Presentations hit every aspect of the scientific spectrum from development of pre-clinical models through retrospective studies on new target therapies and everything in between. Highlights of the conference included the Keynote Lecture by Luke O’Neill of Trinity College Dublin, the Symposium “Mechanisms Underlying Microbiome-Mediated Inflammation”, and multiple discussions on identifying and targeting novel biomarkers of inflammatory diseases.

Read More

Topics: Inflammation, metabolic, Preclinical Discovery, Microbiome, Biomarkers, World Congress on Inflammation

The Pathology of the IL-33/T1/ST2 Pathway: Harmin’ Alarmin

Posted by MD Biosciences on Aug 10, 2015 4:30:00 PM

IL-33 is a member of the IL-1 cytokine family that is expressed constitutively in the nucleus of epithelial and endothelial cells as well as in CNS oligodendrocyte and astrocyte cells (1-2). Its release in response to cell damage and/or death has earned it the classification of “alarmin” – an immunological alarm signal that is released in times of cellular distress (3-4). Upon release, IL-33 binds to the T1/ST2 and IL-1R accessory protein (IL-1RAP) heterodimer complex to activate the MYD88-dependant signaling pathway (1).

Studies targeting the function of IL-33 and/or signaling through its T1/ST2 receptor have highlighted the dual role this versatile cytokine pathway plays in the induction inflammatory immune reactions. More interestingly, these reactions can be either beneficial or pathological in nature. Here we will discuss the pathological role of IL-33 in disease.

Read More

Topics: Dermal, Inflammation, Research Products, Infection, Acute Kidney Injury (AKI)

Bioimaging in Preclinical Models of Rheumatoid Arthritis

Posted by MD Biosciences on Nov 5, 2012 11:12:00 AM

Rheumatoid arthritis is a chronic and progressive inflammatory condition estimated to affect between 0.5-1% of the world's population, with more women being affected than men. It is a systemic disease manifesting mainly as a disabiling destruction of the synovial joints of the hands and feet.

Read More

Topics: Inflammation

eBook: Pain & Inflammation Linkage | Targets in Overlap

Posted by MD Biosciences on Jul 19, 2011 12:34:00 PM

Neuropathic pain presents a wide variety of challenges to researchers, not the least of which is the simple fact that neuropathic pain, by definition, requires neuronal damage, which in turn automatically initiates immune response that often inflicts further neuronal damage. The interactions between the nervous system and immune system in the case of neuropathic pain make for a very complex story that is only beginning to unfold:

Read More

Topics: Pain, Inflammation

Choosing DNCB or FITC-induced Contact Hypersensitivity Models

Posted by MD Biosciences on Jun 1, 2011 9:37:00 AM

Read More

Topics: Dermal, Inflammation

Cardiovascular Disease & Underlying Inflammatory Events

Posted by MD Biosciences on May 10, 2011 2:51:00 PM

Cardiovascular disease (CVD) including heart disease, vascular disease and atherosclerosis are the most critical global health threats.

An estimated 26 million people are living with the effects of heart disease and is a major cause of death in western society. Until recently the widely held belief was that the CVD is simply the process as a build up of fat on the surface of artery walls. Eventually, this build up of fat blocks the artery and a heart attack or stroke occurs. However, the process has now been identified as a disease of the inner artery wall (intima) and inflammation is a key factor in its progression.

Read More

Topics: Inflammation, Cardiovascular

Inflammation & Pain Processing: Customizable Preclinical Models

Posted by MD Biosciences on May 4, 2011 1:46:00 PM


Chronic, destructive inflammation is at the core of a wide variety of diseases and conditions.

Inflammation, whether acute or chronic, is very often associated with pain. Similar to inflammation, pain can be physiological (an adaptive means of protecting tissues from real or perceived danger) or pathological (chronic, and often debilitating despite resolution of the original stimulus). Chronic pain can be caused by a variety of situations including inflammatory diseases such as osteo‐ and rheumatoid arthritis (inflammatory pain), tumor formation (cancer pain), and nerve injury (neuropathic pain).

Read More

Topics: Pain, Inflammation

Link Between TH17 & Osteoclast Function in RA

Posted by MD Biosciences on Apr 19, 2011 11:33:00 AM

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that affects approximately 1% of the population, and in 2010 cost the US alone $39.2 billion (1,2).  The disease is characterized by bone erosion, cartilage damage, synovial hyperplasia and cellular infiltration, all of which result in debilitating joint pain and stiffness (1,3,4).  Studying preclinical models such as the collagen-induced arthritis (CIA) model and the anti-collagen antibody induced arthritis (ACAIA) model, which show the above hallmarks of disease has allowed the identification of the cells and cytokines involved in the pathogenesis of the disease (5,6).
Read More

Topics: Inflammation